Isosorbide Dinitrate (Isordil, Dilitrate-SR, Sorbitrate, Timecelles)

Category:

  • Cardiac

Description:

  • Antianginal agent

Indications:

  • Prevention of angina pectoris

  • Relief of acute anginal episodes and prophylaxis prior to events likely to provoke an attack

  • CHF (non-FDA approved)

  • Hypertension (acute) (non-FDA approved)

Contraindications:

  • Hypersensitivity to nitrates, severe anemia, close-angle glaucoma, postural hypotension

  • Head trauma

Precautions:

  • Pregnancy category C; use caution in nursing mothers

  • Acute MI, hypertrophic cardiomyopathy, glaucoma

  • Volume depletion, hypotension, abrupt withdrawal

  • Continuous delivery without nitrate-free interval (tolerance develops)

Adverse Reactions (Side Effects):

  • CNS: agitation, anxiety, apprehension, confusion, dizziness, dyscoordination, headache, hypoesthesia, hypokinesia, insomnia, nervousness, nightmares, restlessness, vertigo, weakness

  • CV: atrial fibrillation, cardiovascular collapse, crescendo angina, dysrhythmias, edema, hypotension, PVC’s, rebound hypertension, retrosternal discomfort, syncope, tachycardia

  • EENT: blurred vision, diplopia

  • GI: abdominal pain, diarrhea, dyspepsia, involuntary passing of feces, nausea, tenesmus, vomiting

  • GU: dysuria, impotence, involuntary passing of urine, urinary frequency

  • HEME: hemolytic anemia, methemoglobinemia

  • MS: arthralgia, muscle twitching

  • SKIN: cold sweat, crusty skin lesions, exfoliative dermatitis, flushing, pallor, perspiration, pruritis, rash

 

Dosage:

Administered orally: Asymmetric dosing regimens provide a daily nitrate-free interval to minimize the development of tolerance.

  • Adult:   

    • SL 2.5-5mg initially, titrate upward until angina is relieved or side effects limit the dose; 

    • chewable tablets 5mg initially, titrate upward until angina is relieved or side effects limit the dose; 

    • PO 5-20mg 2-3 times daily initially (last dose no later than 1900), maintenance 10-40mg 2-3 times daily (last dose no later than 1900); 

    • PO SUS REL 40mg 1-2 times daily initially (last dose no later than 1400), maintenance 40-80mg 1-2 times daily (last dose no later than 1400)

Special considerations:

  • Headache may be a marker for drug activity; do not try to avoid by altering treatment schedule; aspirin or acetaminophen may be used for relief

  • Dissolve SL tablets under tongue; do not crush, chew, or swallow

  • Do not crush chewable tablets before administering

  • Avoid alcohol

  • Make changes in position slowly to prevent fainting

 

 

Home  ·  Military Medicine  ·  Sick Call  ·  Basic Exams  ·  Medical Procedures  ·  Lab and X-ray  ·  The Pharmacy  ·  The Library  ·  Equipment  ·  Patient Transport  ·  Medical Force Protection  ·  Operational Safety  ·  Operational Settings  ·  Special Operations  ·  Humanitarian Missions  ·  Instructions/Orders  ·  Other Agencies  ·  Video Gallery  ·  Forms  ·  Web Links  ·  Acknowledgements  ·  Help  ·  Feedback

Approved for public release; Distribution is unlimited.

The information contained here is an abbreviated summary. For more detailed and complete information, consult the manufacturer's product information sheets or standard textbooks.

Source: Operational Medicine 2001, Health Care in Military Settings, NAVMED P-5139, May 1, 2001, Bureau of Medicine and Surgery, Department of the Navy, 2300 E Street NW, Washington, D.C., 20372-5300.

Bureau of Medicine and Surgery
Department of the Navy
2300 E Street NW
Washington, D.C
20372-5300

Operational Medicine
 Health Care in Military Settings
CAPT Michael John Hughey, MC, USNR
NAVMED P-5139
  January 1, 2001

United States Special Operations Command
7701 Tampa Point Blvd.
MacDill AFB, Florida
33621-5323

*This web version is provided by The Brookside Associates, LLC.  It contains original contents from the official US Navy NAVMED P-5139, but has been reformatted for web access and includes advertising and links that were not present in the original version. The medical information presented was reviewed and felt to be accurate in 2001. Medical knowledge and practice methods may have changed since that time. Some links may no longer be active. This web version has not been approved by the Department of the Navy or the Department of Defense. The presence of any advertising on these pages does not constitute an endorsement of that product or service by either the US Department of Defense or the Brookside Associates. The Brookside Associates is a private organization, not affiliated with the United States Department of Defense.

© 2015, Brookside Associates, LLC. All rights reserved

Other Brookside Products

 

 

Advertise on this site